Payment overview · 2025
General Payments
$2,241.91
112 reported records · 20 companies
Healthcare provider profile · identity verified
Kailash C. Sharma, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OAK FOREST, IL · NPI 1407855083
Verified facts
What the public records show
CMS Open Payments records show Kailash C. Sharma, M.D. received $2,241.91 in general payments during 2025 across 112 reported records.
GlaxoSmithKline, LLC. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $534.19 | 23.8% | 48 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $375.64 | 16.8% | 12 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $246.92 | 11.0% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $207.05 | 9.2% | 6 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $146.03 | 6.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.13 | 5.4% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $77.97 | 3.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.53 | 2.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.45 | 2.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.16 | 2.7% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $56.07 | 2.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $46.78 | 2.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.29 | 2.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $44.98 | 2.0% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $42.79 | 1.9% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $41.92 | 1.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.42 | 1.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.92 | 0.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $14.80 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.87 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,241.91 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $413.95 | 36 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $302.99 | 10 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $210.88 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $207.05 | 6 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $184.52 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $120.24 | 12 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $119.06 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $114.45 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $105.41 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $77.97 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $61.45 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.16 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.16 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.69 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $46.78 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $44.98 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $42.79 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $41.92 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| ComfortGel Normalized: comfortgel |
Device | Philips North America LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $10.77 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 103 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 50 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
138 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
103 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 305 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 91 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 276 | 97 |
| Metformin Hcl | Metformin Hcl | 240 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 62 |
| Methylprednisolone | Methylprednisolone | 204 | 122 |
| Prednisone | Prednisone | 188 | 92 |
| Clonazepam | Clonazepam | 182 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 45 |
| Lisinopril | Lisinopril | 160 | 49 |
| Azithromycin | Azithromycin | 153 | 79 |
| Furosemide | Furosemide | 153 | 46 |
| Breo Ellipta | Fluticasone/Vilanterol | 144 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 138 | 28 |
| Alprazolam | Alprazolam | 126 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 54 |
| Gabapentin | Gabapentin | 115 | 34 |
| Ozempic | Semaglutide | 115 | 25 |
| Jardiance | Empagliflozin | 103 | 28 |
| Losartan Potassium | Losartan Potassium | 102 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 28 |
| Simvastatin | Simvastatin | 101 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 27 |
| Farxiga | Dapagliflozin Propanediol | 91 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 21 |
| Tramadol Hcl | Tramadol Hcl | 78 | 15 |
| Allopurinol | Allopurinol | 75 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Omeprazole | Omeprazole | 65 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 20 |
| Meloxicam | Meloxicam | 60 | 17 |
| Chlorthalidone | Chlorthalidone | 58 | 14 |
| Glipizide | Glipizide | 56 | 17 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Eliquis | Apixaban | 55 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 16 |
| Valsartan | Valsartan | 53 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 19 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Tradjenta | Linagliptin | 51 | suppressed |
| Rybelsus | Semaglutide | 50 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 21 |
| Carvedilol | Carvedilol | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 31 |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Dupixent Pen | Dupilumab | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Clonidine | Clonidine | 31 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Nystatin | Nystatin | 29 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nystop | Nystatin | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,241.91 · 112 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Arikayce, BREZTRI, ComfortGel, DUPIXENT, FASENRA, GLASSIA, JARDIANCE, Kerendia, Leqembi, MOUNJARO, NUCALA, Ohtuvayre, Ozempic, Rybelsus, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, WAKIX, Wegovy, XIFAXAN, XYWAV, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error